“The approval is credit positive because of incremental profit and cash flow from sales of the vaccine,” Moody’s said https:// “The revenue and profit opportunities for Pfizer are significant because it has priced the vaccine at a profit.”
The Pfizer/BioNTech vaccine in a large clinical trial was 95% effective in preventing illness. U.S. regulators late on Friday authorized emergency use of the vaccine, following similar moves by the UK and Canada.
Source: Economy - investing.com
